Precise Neoadjuvant Chemoresection of Low Grade NMIBC
Conditions: Bladder Cancer; Non-muscle Invasive Bladder Cancer; Low-risk Interventions: Drug: Epirubicin; Drug: Mitomycin; Drug: Gemcitabine; Drug: Docetaxel Sponsors: University of Bern; Spitalzentrum Biel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Docetaxel | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Taxotere